AAPG — ASCENTAGE PHARMA GROUP INTERNATIONAL

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2023311 · China
Last close
$13.14
Market Cap
$1.23B
52W High
$33.09
52W Low
$13.12
ADV30
7,648
Next earnings
2026-08-19

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 3,240,702,000 1,895,583,000 2,674,869,000
Dec 2025 — — — — 3,963,577,000 2,464,400,000 2,629,365,000
Jun 2025 — — — — 3,046,144,000 1,661,454,000 2,370,235,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-7,830,018,000
Inventory
$64,300,000
Receivables
$333,381,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$642,635,008
EBITDA
$-1,335,864,064
Free Cash Flow
$-956,540,352
Enterprise Value
$1,710,758,016
Total Cash
$1,895,582,976
Total Debt
$2,094,571,008
Shares Out
93,388,942
Trailing EPS
$-2.35
Book Value
$0.89
ROE
-236.6%
ROA
-28.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 574,120,000 -1,197,691,000 -1,242,769,000 3,963,577,000 2,629,365,000 1,324,462,000 -1,174,128,000
Dec 2024 980,650,000 -369,730,000 -405,433,000 2,617,810,000 2,343,648,000 264,194,000 -111,357,000
Dec 2023 221,984,000 -872,636,000 -925,637,000 2,500,393,000 2,429,761,000 60,417,000 -726,077,000
Dec 2022 209,711,000 -849,810,000 -882,924,000 2,830,261,000 2,421,603,000 408,658,000 -653,915,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.04

Peers — same industry

TickerNameMarket CapLastDaily %
NKTR NEKTAR THERAPEUTICS $1.23B $35.91 —
SLN Silence Therapeutics plc $1.23B $19.80 —
KARD Kardigan, Inc. $1.23B $13.19 —
SLNCF Silence Therapeutics plc $1.22B $6.53 —
AMPH Amphastar Pharmaceuticals, Inc. $1.24B $29.10 —

News headlines (Yahoo Finance, 1h cache)

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
2026-11-15 23:30 · Yahoo
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
2026-11-04 23:30 · Yahoo
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
2026-11-03 12:30 · Yahoo
Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
2026-10-20 23:30 · Yahoo
Ascentage Pharma (SEHK:6855) Stock Looks Above Fair Value After The Fall
2026-10-19 19:14 · Yahoo
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
2026-10-10 14:35 · Yahoo
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
2026-10-05 14:55 · Yahoo
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
ASCENTAGE PHARMA GROUP INTERNATIONAL Q2 2026 Earnings Call Summary
2026-08-21 12:30 · Yahoo
Ascentage Pharma Group International H1 Earnings Call Highlights
2026-08-20 15:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.